HitGen, Nitrase partner for library-based drug discovery
Nitrase Therapeutics is deploying its NITROME platform for developing several therapies that target nitrases, a new enzymes class discovered by the company. The platform has created leads for
The designation will potentially facilitate the development and accelerate new therapies review for treating serious conditions which have unmet medical need. Moleculin noted that the company is now
The multi-target, multi-year partnership will combine the clinical and commercial knowledge of Rallybio in rare diseases with AbCellera’s antibody discovery engine for identifying optimal clinical candidates and providing
The second-generation PDT photosensitiser drug, REM-001 has undergone late-stage clinical development in previous clinical trials. The REM-001 therapy includes three parts, a laser light source, a light delivery
The application has been submitted for the combination of toripalimab, cisplatin and gemcitabine as the first-line treatment for locally recurrent or metastatic nasopharyngeal carcinoma (NPC) patients. The company